William Lewis, who serves as both Chair and Chief Executive Officer of Insmed Inc (NASDAQ:INSM), sold 10,700 shares of the biopharmaceutical company's common stock on April 6, 2026, bringing in $1,746,335. The sales were executed at prices ranging from $161.73 to $164.01. At the time of the report, the stock was trading at $160.18, which remains below its 52-week high of $212.75 despite a 151% increase over the previous year.
On the same day as the sale, Lewis exercised stock options that resulted in the acquisition of 10,699 shares of Insmed common stock. Those option exercises were completed at strike prices of $30.46 and $17.16 and, in aggregate, amounted to $266,839.
After completing the sale and the option exercises, Lewis directly owns 301,185 shares of Insmed common stock. An additional 233,924 shares are held indirectly through the Katie Procter Dynasty Trust.
Market research available through InvestingPro indicates that, at current trading levels, Insmed appears overvalued relative to its Fair Value. While InvestingPro Tips emphasize the stock's strong momentum, the research notes that analysts do not expect the company to record profitability this year. The platform offers additional ProTips and a detailed Pro Research Report for subscribers seeking deeper analysis.
In other company developments, Insmed announced it would discontinue its hidradenitis suppurativa program after the Phase 2b CEDAR study did not meet its primary or secondary efficacy endpoints. The trial had tested brensocatib in adults with moderate to severe hidradenitis suppurativa. The negative outcome prompted several broker-dealers to adjust their models and targets.
Following the trial results, H.C. Wainwright lowered its price target for Insmed to $220 while retaining a Buy rating. Stifel kept a Buy rating with a $208 price target, noting that the unfavorable outcome was anticipated given the absence of validation in the disease setting. Mizuho revised its price target to $202 from $206, citing the removal of the indication from its financial model. Truist Securities maintained a Buy rating and kept a $205 price target after the trial failed to meet endpoints. Collectively, these moves reflect the company's recent challenges in advancing brensocatib for this chronic skin condition.
Investors evaluating whether INSM represents a value opportunity are presented with contrasting signals: significant insider activity and recent price appreciation on one hand, and clinical setbacks with attendant analyst adjustments on the other. The company's near-term profitability outlook remains uncertain according to available analyst commentary.